Siemens gets EU OK for Dade buy:
This article was originally published in Clinica
Executive Summary
German multinational Siemens is closer to clinching its third IVD buy, after its proposed acquisition of Dade Behring received European antitrust approval yesterday. The deal had cleared US regulatory hurdles in September. Siemens said it expects to complete the transaction shortly after the expiration of its cash tender offer at midnight, October 31. Siemens entered an agreement in July to buy Dade for $7bn in cash ($77 per share) - the move is in line with the Erlangen-based group's strategy to become a full-service diagnostics company (see Clinica No 1267, p 1).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.